Kymera Therapeutics, Inc. (KYMR): Capital Expenditures
$1.45M
Year ended 2025-12-31
$1.19M
Trailing 12 months to 2026-06-30
-20.1%
3-year compound annual growth
-30.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.45M | -88.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $12.84M | -62.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $34.48M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $2.84M | +77.6% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $1.60M | -82.4% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $9.10M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $532.0K | n/a | 2022-02-24, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.45M | -88.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $102.0K | -61.8% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $607.0K | -93.1% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $607.0K | +237.2% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $133.0K | n/a |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $1.64M | +27.8% |
Compare KYMR, SGMOQ, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗